newsfilter
← Latest News
GlobeNewswire·

A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next

CNXUFAANABCVEMPC
  • Conexeu Sciences Inc. (NASDAQ: CNXU) is developing its investigational CXU™ platform to address the demand for large-volume body restoration following rapid weight loss from GLP-1 medications.
  • The company completed a 12-month P.R.O.O.F.™ preclinical study in animal models to evaluate the performance of its flowable collagen scaffold, with detailed findings reserved for future peer-reviewed publication.
  • CXU™ is designed to restore natural body fullness through a needle rather than surgery, aiming to fill a market gap where current injectables cannot provide large-volume restoration & surgical options suffer from high reabsorption rates.
  • Boston Consulting Group projects that provider revenue from GLP-1-related aesthetic care will grow from approximately $0.7 billion to $2.0 billion by 2030.
  • The company targets a predicate-based U.S. regulatory strategy with an anticipated 510(k) submission in the first quarter of 2027, subject to required testing & documentation.
  • Conexeu holds all rights to the CXU™ platform across more than 40 jurisdictions & plans to scale the single formula & device system across wound care, periodontal, aesthetic, & veterinary markets.
  • The article compares Conexeu's platform strategy to the growth patterns of companies like First Advantage, AnaptysBio, Cenovus Energy, & Marathon Petroleum as examples of scalable, trusted infrastructure.
  • Conexeu is currently a preclinical-stage company, & the P.R.O.O.F.™ study results are not peer-reviewed, not predictive of human outcomes, & do not represent commercial launch or regulatory clearance.
  • The publication is identified as a paid advertisement by Energy Metal News on behalf of Conexeu Sciences Inc., with disclosures noting potential conflicts of interest & risks associated with investing in securities.